Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the ...

Medicare Advantage plans are squeezing billions out of the federal government by billing more for patient care, a new study ...

"I've said this before, but as more data comes in I become more convinced that we may look back on these drugs as the ...

Prior to Friday's decision, the Obesity Action Coalition along with 80 other organizations sent a letter to HHS Secretary ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

11 NEWS GETS THE FACTS ON OZEMPIC, WEGOVY ... not expected to be finalized until Trump took office. Medicare does pay for drugs like Wegovy for patients who have heart disease and need to reduce ...

CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they ...